Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerating science and advancing human health, today announced a research collaboration with Cleveland Clinic, a nonprofit ...

10x Genomics TXG recently entered into a multi-year research collaboration with the Cleveland Clinic to advance novel ...

As the Human Cell Atlas project marks its 10th anniversary, a leader's ties to a major single-cell RNA sequencing company ...

The past six months have been a windfall for 10x Genomics’s shareholders. The company’s stock price has jumped 116%, setting ...

10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, and the A*STAR Genome Institute of Singapore (A*STAR GIS), today announced a research collaboration for the Target ...

Transaction and post-transaction values based on SEC Form 4 weighted average price ($24.54). 10x Genomics offers single cell and spatial genomics instruments, consumables, and software, including ...

"Our team delivered solid sequential revenue growth over last quarter," said Serge Saxonov, Co-founder and CEO of 10x Genomics. "We are confident the work we've done throughout 2024 sets us up well ...

Arc Institute continues its work to generate and share large-scale, high-quality datasets of cell state before and after chemical or genetic perturbations to enable “virtual cell” models and other ...

Precision medicine company CareDx and 10x Genomics have partnered to launch ImmuneScape, a multiomics program to improve the understanding of transplant organ rejection and variability in patient ...

Across the recent three months, 6 analysts have shared their insights on 10x Genomics (NASDAQ:TXG), expressing a variety of opinions spanning from bullish to bearish. The table below summarizes their ...

That occurred on Monday, when Tejas Savant from white-shoe investment bank Morgan Stanley reduced his 10x Genomics price target to $18 per share, far down from his previous level of $26. Despite that, ...